Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education.
Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.
In these highlights from the ClinicalThought program, Sarah Donahue, MPH, NP; David B. Page, MD; Hope S. Rugo, MD; and Peter Schmid, MD, PhD, FRCP, discuss the latest developments in immuno-oncology strategies for managing metastatic triple-negative breast cancer (TNBC), including optimal use of immune checkpoint inhibition, toxicity management, and future directions.
CCO plans to measure the educational impact of this activity, and some questions in this activity will be asked twice: once prior to the discussion that informs the best choice and then once again after that specific discussion. Your responses will be aggregated for analysis, and your specific responses will not be shared.
Before continuing with this educational activity, please take a moment to answer the following questions.